NCT00498914View on ClinicalTrials.gov

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory
Interventions
DRUG

YM155

Continuous IV infusion

Trial Locations (22)

19111

Philadelphia

27157

Winston-Salem

28041

Madrid

30322

Atlanta

33076

Bordeaux

33136

Miami

34295

Montpellier

37044

Tours

44093

Nantes

63110

St Louis

71130

Shreveport

76038

Rouen

77303

Houston

78229

San Antonio

80045

Aurora

86021

Poitiers

90211

Beverly Hills

94305

Palo Alto

97213

Portland

K1H 8L6

Ottawa

06200

Nice

08035

Barcelona

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00498914 - Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects | Biotech Hunter | Biotech Hunter